First Allied Advisory Services’s Phio Pharmaceuticals PHIO Stock Holding History

First Allied Advisory Services’s Portfolio PHIO Stock Details PHIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2	Closed	-$22K	–	1229
2018 Q2	$22K	Sell	2 -1	-33%	-$14.8K	﹤0.01%	1140
2018 Q1	$64K	Buy	+3	New	+$69K	﹤0.01%	1143

Other funds holding PHIO

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Allied Advisory Services's PHIO Position: Q3 2018 in Review

First Allied Advisory Services sold out of Phio Pharmaceuticals (PHIO) in Q3 2018, closing a stake of 2 shares — an estimated $22K sold.

First Allied Advisory Services first reported a position in PHIO in Q1 2018 and held it in 2 quarters. The position peaked at $64K in Q1 2018. 7 funds tracked by Wall St. Rank hold PHIO as of Q3 2018.

First Allied Advisory Services reported no remaining Phio Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
First Allied Advisory Services sold 2 Phio Pharmaceuticals shares in Q3 2018, an estimated $22K.
First Allied Advisory Services first reported a position in Phio Pharmaceuticals in Q1 2018 and held it in 2 quarters.
First Allied Advisory Services's Phio Pharmaceuticals position peaked at $64K in Q1 2018.
7 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2018.

Based on First Allied Advisory Services's 13F filing for Q3 2018, filed 14 Nov 2018.